T细胞疗法-话题@MedSci

#T细胞疗法#

96篇内容 | 3990人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2258929, encodeId=006d2258929eb, content=<a href='/topic/show?id=06a2e1405a8' target=_blank style='color:#2F92EE;'>#癌症治疗#</a> <a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, objectTitle=双特异性嵌合TCR-T细胞治疗：攻克癌症异质性的下一代免疫疗法, objectType=article, longId=870099, objectId=92618e009989, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/doctor-writing-D3K6QME.jpg, objectUrl=/article/show_article.do?id=92618e009989, replyNumber=0, likeNumber=21, createdTime=2025-04-03, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=92618e009989, moduleTitle=双特异性嵌合TCR-T细胞治疗：攻克癌症异质性的下一代免疫疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=92618e009989)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2246885, encodeId=eaab224688578, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a> 2024年，癌症药物开发领域经历了重大的变革，特别是在T细胞疗法和针对难治性癌症的小分子药物方面取得了显著进展。这一年见证了针对实体瘤的T细胞疗法获得批准，以及新型小分子药物为传统治疗手段难以应对的癌症提供了新的治疗选择。这些进展不仅反映了行业优先级的变化，也指示了最具创新性和变革性疗法的发展方向。在此背景下，Elie Dolgin 在国际顶尖期刊 Nature Cancer 上发表了题为 Cancer drug approvals and setbacks in 2024 的文章【1】，回顾了2024年癌症新药获批情况，以及其它抗癌疗法的研发进展。, objectTitle=T细胞疗法, objectType=topic, longId=18030, objectId=null, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=null, replyNumber=0, likeNumber=12, createdTime=2025-01-06, rootId=0, userName=yangchou, userId=88b489038, projectId=1, avatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, status=1, hasArticle=0, attachment=null, ipAttribution=浙江省, moduleDTOList=null, followStatus=false, userIsMember=false, type=1, lengthMark=1), GetTopicListResponse(id=2246883, encodeId=0a2f2246883c0, content=<a href='/topic/show?id=06a2e1405a8' target=_blank style='color:#2F92EE;'>#癌症治疗#</a> <a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, objectTitle=Nat Cancer：2024癌症药物七大突破，特别在这两个领域取得显著进展！, objectType=article, longId=858415, objectId=a6bc85841541, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240516/1715852948191_5579292.png, objectUrl=/article/show_article.do?id=a6bc85841541, replyNumber=0, likeNumber=26, createdTime=2025-01-06, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=a6bc85841541, moduleTitle=Nat Cancer：2024癌症药物七大突破，特别在这两个领域取得显著进展！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a6bc85841541)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2210542, encodeId=18ce22105422b, content=<a href='/topic/show?id=c8ee32526f3' target=_blank style='color:#2F92EE;'>#前列腺癌#</a> <a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a> <a href='/topic/show?id=02b011566669' target=_blank style='color:#2F92EE;'>#PSCA-CAR T#</a>, objectTitle=Nature Medicine：前列腺癌治疗新篇章：PSCA-CAR T细胞疗法1期临床试验揭示初步成效, objectType=article, longId=829127, objectId=ec9d82912e28, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240617/1718602549381_5579292.jpg, objectUrl=/article/show_article.do?id=ec9d82912e28, replyNumber=0, likeNumber=116, createdTime=2024-06-18, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=ec9d82912e28, moduleTitle=Nature Medicine：前列腺癌治疗新篇章：PSCA-CAR T细胞疗法1期临床试验揭示初步成效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ec9d82912e28)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2161531, encodeId=1f0a216153127, content=<a href='/topic/show?id=daf52906537' target=_blank style='color:#2F92EE;'>#免疫治疗#</a>2.0，<a href='/topic/show?id=d536e14259d' target=_blank style='color:#2F92EE;'>#癌症疫苗#</a>联合<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>治疗反复耐药<a href='/topic/show?id=08f236865a8' target=_blank style='color:#2F92EE;'>#卵巢癌#</a>，70%病情控制率，生存期翻倍！完成该治疗方案的患者中位总生存时间达到了14.2个月，这个是相当牛的!! 未来其它瘤肿可能也是相似的! 需要<a href='/topic/show?id=f7872914569' target=_blank style='color:#2F92EE;'>#免疫联合治疗#</a> , objectTitle=免疫治疗2.0，癌症疫苗联合T细胞疗法治疗反复耐药卵巢癌，70%病情控制率，生存期翻倍！, objectType=article, longId=794926, objectId=abe3e9492692, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20221109/1668016299208_4754896.png, objectUrl=/article/show_article.do?id=abe3e9492692, replyNumber=0, likeNumber=151, createdTime=2023-10-08, rootId=0, userName=侠胆医心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=abe3e9492692, moduleTitle=免疫治疗2.0，癌症疫苗联合T细胞疗法治疗反复耐药卵巢癌，70%病情控制率，生存期翻倍！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=abe3e9492692)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478074, encodeId=d33414e807448, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, objectTitle=CAR-T之父最新Nature论文！无需放化疗，新型T细胞疗法成功治愈超半数难治型实体瘤小鼠, objectType=article, longId=731697, objectId=1fbce3169782, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1fbce3169782, replyNumber=0, likeNumber=102, createdTime=2022-07-10, rootId=0, userName=124984edm24暂无昵称, userId=6bea7392214, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1fbce3169782, moduleTitle=CAR-T之父最新Nature论文！无需放化疗，新型T细胞疗法成功治愈超半数难治型实体瘤小鼠, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1fbce3169782)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478073, encodeId=e47214e80738d, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, objectTitle=CAR-T之父最新Nature论文：无需放化疗，合成IL-9受体增强T细胞疗法，治愈实体肿瘤, objectType=article, longId=729830, objectId=b041e298307f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b041e298307f, replyNumber=0, likeNumber=112, createdTime=2022-06-19, rootId=0, userName=124984edm24暂无昵称, userId=6bea7392214, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b041e298307f, moduleTitle=CAR-T之父最新Nature论文：无需放化疗，合成IL-9受体增强T细胞疗法，治愈实体肿瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b041e298307f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478072, encodeId=e8b614e80727c, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, objectTitle=Cancer Discov：阻断TIGIT有望改善靶向CD19的CAR-T细胞疗法对非霍奇金淋巴瘤的疗效, objectType=article, longId=728112, objectId=d043e28112d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d043e28112d0, replyNumber=0, likeNumber=82, createdTime=2022-05-30, rootId=0, userName=124984edm24暂无昵称, userId=6bea7392214, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d043e28112d0, moduleTitle=Cancer Discov：阻断TIGIT有望改善靶向CD19的CAR-T细胞疗法对非霍奇金淋巴瘤的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d043e28112d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478071, encodeId=9e2014e807174, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, objectTitle=AACR 2022：BioNTech的CAR-T细胞疗法治疗实体瘤，疗效确切, objectType=article, longId=724120, objectId=4f46e241201a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4f46e241201a, replyNumber=0, likeNumber=94, createdTime=2022-04-14, rootId=0, userName=124984edm24暂无昵称, userId=6bea7392214, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4f46e241201a, moduleTitle=AACR 2022：BioNTech的CAR-T细胞疗法治疗实体瘤，疗效确切, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4f46e241201a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478070, encodeId=624014e807091, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, objectTitle=CAR-T细胞疗法Yescarta获得FDA批准用于早期治疗淋巴瘤, objectType=article, longId=723516, objectId=7576e23516c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7576e23516c3, replyNumber=0, likeNumber=101, createdTime=2022-04-06, rootId=0, userName=124984edm24暂无昵称, userId=6bea7392214, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7576e23516c3, moduleTitle=CAR-T细胞疗法Yescarta获得FDA批准用于早期治疗淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7576e23516c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478069, encodeId=282114e806985, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, objectTitle=FDA公布基因编辑与CAR-T细胞疗法两份指南草案，提出这些建议, objectType=article, longId=301462, objectId=79c4301462ab, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=79c4301462ab, replyNumber=0, likeNumber=94, createdTime=2022-03-24, rootId=0, userName=124984edm24暂无昵称, userId=6bea7392214, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=79c4301462ab, moduleTitle=FDA公布基因编辑与CAR-T细胞疗法两份指南草案，提出这些建议, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=79c4301462ab)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478068, encodeId=ef3a14e806897, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, objectTitle=由于患者死亡，CAR-T细胞疗法ATA2271的临床试验被暂停, objectType=article, longId=299319, objectId=aae0299319f3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aae0299319f3, replyNumber=0, likeNumber=118, createdTime=2022-02-23, rootId=0, userName=124984edm24暂无昵称, userId=6bea7392214, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aae0299319f3, moduleTitle=由于患者死亡，CAR-T细胞疗法ATA2271的临床试验被暂停, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aae0299319f3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478067, encodeId=d4ff14e8067a6, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, objectTitle=Blood：采用CAR T细胞疗法(liso-cel)治疗复发性/难治性CLL/SLL, objectType=article, longId=220308, objectId=35f022030877, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=35f022030877, replyNumber=0, likeNumber=100, createdTime=2021-11-15, rootId=0, userName=124984edm24暂无昵称, userId=6bea7392214, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=35f022030877, moduleTitle=Blood：采用CAR T细胞疗法(liso-cel)治疗复发性/难治性CLL/SLL, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=35f022030877)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478066, encodeId=e0d414e8066c6, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, objectTitle=武田将收购GammaDelta Therapeutics，以加速开发针对实体瘤的异体γδT细胞疗法, objectType=article, longId=219603, objectId=6d1621960324, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6d1621960324, replyNumber=0, likeNumber=108, createdTime=2021-11-03, rootId=0, userName=124984edm24暂无昵称, userId=6bea7392214, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6d1621960324, moduleTitle=武田将收购GammaDelta Therapeutics，以加速开发针对实体瘤的异体γδT细胞疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6d1621960324)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478065, encodeId=c38e14e806533, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, objectTitle=Treadwell Therapeutics宣布收购专注于新型TCR-T细胞疗法的TIO Bioventures投资组合公司TCRyption Inc., objectType=article, longId=218899, objectId=169221889999, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=169221889999, replyNumber=0, likeNumber=91, createdTime=2021-10-21, rootId=0, userName=124984edm24暂无昵称, userId=6bea7392214, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=169221889999, moduleTitle=Treadwell Therapeutics宣布收购专注于新型TCR-T细胞疗法的TIO Bioventures投资组合公司TCRyption Inc., moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=169221889999)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478064, encodeId=d29314e8064a8, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, objectTitle=NEJM：CAR-T细胞疗法首次成功治疗红斑狼疮, objectType=article, longId=215829, objectId=75e621582978, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=75e621582978, replyNumber=0, likeNumber=104, createdTime=2021-08-18, rootId=0, userName=124984edm24暂无昵称, userId=6bea7392214, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=75e621582978, moduleTitle=NEJM：CAR-T细胞疗法首次成功治疗红斑狼疮, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=75e621582978)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478063, encodeId=d55b14e8063b6, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, objectTitle=Blood：糖皮质激素对CAR-T细胞疗法治疗的大B细胞淋巴瘤患者预后的影响, objectType=article, longId=212729, objectId=d16b212e29ab, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d16b212e29ab, replyNumber=0, likeNumber=110, createdTime=2021-06-16, rootId=0, userName=124984edm24暂无昵称, userId=6bea7392214, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d16b212e29ab, moduleTitle=Blood：糖皮质激素对CAR-T细胞疗法治疗的大B细胞淋巴瘤患者预后的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d16b212e29ab)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478062, encodeId=68dd14e80623b, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, objectTitle=NEJM：抗B细胞成熟抗原CAR-T细胞疗法bb2121治疗多发性骨髓瘤的效果, objectType=article, longId=211106, objectId=51f721110637, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=51f721110637, replyNumber=0, likeNumber=101, createdTime=2021-05-12, rootId=0, userName=124984edm24暂无昵称, userId=6bea7392214, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=51f721110637, moduleTitle=NEJM：抗B细胞成熟抗原CAR-T细胞疗法bb2121治疗多发性骨髓瘤的效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=51f721110637)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478061, encodeId=f25e14e806198, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, objectTitle=Bone Marrow Transplant：供体源性抗CD19的CAR-T细胞疗法可安全有效的治疗异体造血干细胞移植后复发的B-ALL, objectType=article, longId=210740, objectId=e5eb210e403b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e5eb210e403b, replyNumber=0, likeNumber=91, createdTime=2021-05-03, rootId=0, userName=124984edm24暂无昵称, userId=6bea7392214, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e5eb210e403b, moduleTitle=Bone Marrow Transplant：供体源性抗CD19的CAR-T细胞疗法可安全有效的治疗异体造血干细胞移植后复发的B-ALL, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e5eb210e403b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478060, encodeId=84f314e806047, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, objectTitle=日本厚生劳动省批准CAR-T细胞疗法Breyanzi治疗DLBCL和滤泡性淋巴瘤, objectType=article, longId=209158, objectId=40ec209158b9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=40ec209158b9, replyNumber=0, likeNumber=105, createdTime=2021-03-31, rootId=0, userName=124984edm24暂无昵称, userId=6bea7392214, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=40ec209158b9, moduleTitle=日本厚生劳动省批准CAR-T细胞疗法Breyanzi治疗DLBCL和滤泡性淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=40ec209158b9)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

T细胞疗法

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#癌症治疗# #T细胞疗法#

双特异性嵌合TCR-T细胞治疗：攻克癌症异质性的下一代免疫疗法

2025-04-03

yangchou (审核中...)

前往app查看评论内容

全文收起 #T细胞疗法# 2024年，癌症药物开发领域经历了重大的变革，特别是在T细胞疗法和针对难治性癌症的小分子药物方面取得了显著进展。这一年见证了针对实体瘤的T细胞疗法获得批准，以及新型小分子药物为传统治疗手段难以应对的癌症提供了新的治疗选择。这些进展不仅反映了行业优先级的变化，也指示了最具创新性和变革性疗法的发展方向。在此背景下，Elie Dolgin 在国际顶尖期刊 Nature Cancer 上发表了题为 Cancer drug approvals and setbacks in 2024 的文章【1】，回顾了2024年癌症新药获批情况，以及其它抗癌疗法的研发进展。

2025-01-06发表于浙江省

梅斯管理员 (审核中...)

前往app查看评论内容

#癌症治疗# #T细胞疗法#

Nat Cancer：2024癌症药物七大突破，特别在这两个领域取得显著进展！

2025-01-06发表于陕西省

梅斯管理员 (审核中...)

前往app查看评论内容

#前列腺癌# #T细胞疗法# #PSCA-CAR T#

Nature Medicine：前列腺癌治疗新篇章：PSCA-CAR T细胞疗法1期临床试验揭示初步成效

2024-06-18发表于上海

侠胆医心 (审核中...)

前往app查看评论内容

#免疫治疗#2.0，#癌症疫苗#联合#T细胞疗法#治疗反复耐药#卵巢癌#，70%病情控制率，生存期翻倍！完成该治疗方案的患者中位总生存时间达到了14.2个月，这个是相当牛的!! 未来其它瘤肿可能也是相似的! 需要#免疫联合治疗#

免疫治疗2.0，癌症疫苗联合T细胞疗法治疗反复耐药卵巢癌，70%病情控制率，生存期翻倍！

2023-10-08发表于上海

124984edm24暂无昵称 (审核中...)

前往app查看评论内容

#T细胞疗法#

CAR-T之父最新Nature论文！无需放化疗，新型T细胞疗法成功治愈超半数难治型实体瘤小鼠

2022-07-10

124984edm24暂无昵称 (审核中...)

前往app查看评论内容

#T细胞疗法#

CAR-T之父最新Nature论文：无需放化疗，合成IL-9受体增强T细胞疗法，治愈实体肿瘤

2022-06-19

124984edm24暂无昵称 (审核中...)

前往app查看评论内容

#T细胞疗法#

Cancer Discov：阻断TIGIT有望改善靶向CD19的CAR-T细胞疗法对非霍奇金淋巴瘤的疗效

2022-05-30

124984edm24暂无昵称 (审核中...)

前往app查看评论内容

#T细胞疗法#

AACR 2022：BioNTech的CAR-T细胞疗法治疗实体瘤，疗效确切

2022-04-14

124984edm24暂无昵称 (审核中...)

前往app查看评论内容

#T细胞疗法#

CAR-T细胞疗法Yescarta获得FDA批准用于早期治疗淋巴瘤

2022-04-06

124984edm24暂无昵称 (审核中...)

前往app查看评论内容

#T细胞疗法#

FDA公布基因编辑与CAR-T细胞疗法两份指南草案，提出这些建议

2022-03-24

124984edm24暂无昵称 (审核中...)

前往app查看评论内容

#T细胞疗法#

由于患者死亡，CAR-T细胞疗法ATA2271的临床试验被暂停

2022-02-23

124984edm24暂无昵称 (审核中...)

前往app查看评论内容

#T细胞疗法#

Blood：采用CAR T细胞疗法(liso-cel)治疗复发性/难治性CLL/SLL

2021-11-15

124984edm24暂无昵称 (审核中...)

前往app查看评论内容

#T细胞疗法#

武田将收购GammaDelta Therapeutics，以加速开发针对实体瘤的异体γδT细胞疗法

2021-11-03

124984edm24暂无昵称 (审核中...)

前往app查看评论内容

#T细胞疗法#

Treadwell Therapeutics宣布收购专注于新型TCR-T细胞疗法的TIO Bioventures投资组合公司TCRyption Inc.

2021-10-21

124984edm24暂无昵称 (审核中...)

前往app查看评论内容

#T细胞疗法#

NEJM：CAR-T细胞疗法首次成功治疗红斑狼疮

2021-08-18

124984edm24暂无昵称 (审核中...)

前往app查看评论内容

#T细胞疗法#

Blood：糖皮质激素对CAR-T细胞疗法治疗的大B细胞淋巴瘤患者预后的影响

2021-06-16

124984edm24暂无昵称 (审核中...)

前往app查看评论内容

#T细胞疗法#

NEJM：抗B细胞成熟抗原CAR-T细胞疗法bb2121治疗多发性骨髓瘤的效果

2021-05-12

124984edm24暂无昵称 (审核中...)

前往app查看评论内容

#T细胞疗法#

Bone Marrow Transplant：供体源性抗CD19的CAR-T细胞疗法可安全有效的治疗异体造血干细胞移植后复发的B-ALL

2021-05-03

124984edm24暂无昵称 (审核中...)

前往app查看评论内容

#T细胞疗法#

日本厚生劳动省批准CAR-T细胞疗法Breyanzi治疗DLBCL和滤泡性淋巴瘤

2021-03-31

科室
- - 订阅+
  - 更多科室
工具
服务